These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 22946654)

  • 1. Targeting T-cell migration in inflammatory bowel disease.
    Marsal J; Agace WW
    J Intern Med; 2012 Nov; 272(5):411-29. PubMed ID: 22946654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells.
    Caruso R; Fina D; Peluso I; Stolfi C; Fantini MC; Gioia V; Caprioli F; Del Vecchio Blanco G; Paoluzi OA; Macdonald TT; Pallone F; Monteleone G
    Gastroenterology; 2007 Jan; 132(1):166-75. PubMed ID: 17241869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNFα treatment.
    Veltkamp C; Anstaett M; Wahl K; Möller S; Gangl S; Bachmann O; Hardtke-Wolenski M; Länger F; Stremmel W; Manns MP; Schulze-Osthoff K; Bantel H
    Gut; 2011 Oct; 60(10):1345-53. PubMed ID: 21459928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease.
    Van Assche G; Rutgeerts P
    Am J Physiol Gastrointest Liver Physiol; 2005 Feb; 288(2):G169-74. PubMed ID: 15647604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic approaches in inflammatory bowel disease based on the immunopathogenesis.
    Siegmund B; Zeitz M
    Rocz Akad Med Bialymst; 2004; 49():22-30. PubMed ID: 15631310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apoptosis as a therapeutic tool in IBD?
    Lügering A; Lebiedz P; Koch S; Kucharzik T
    Ann N Y Acad Sci; 2006 Aug; 1072():62-77. PubMed ID: 17057191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in inflammatory bowel disease: Novel and emerging treatments.
    Catalan-Serra I; Brenna Ø
    Hum Vaccin Immunother; 2018; 14(11):2597-2611. PubMed ID: 29624476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting T and B lymphocytes in inflammatory bowel diseases: lessons from clinical trials.
    Gerner RR; Moschen AR; Tilg H
    Dig Dis; 2013; 31(3-4):328-35. PubMed ID: 24246983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New therapies for inflammatory bowel disease: from the bench to the bedside.
    Danese S
    Gut; 2012 Jun; 61(6):918-32. PubMed ID: 22115827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modifying T-cell trafficking to the intestinal as a potential management for inflammatory bowel disease.
    Lawrance IC
    Expert Opin Investig Drugs; 2012 Jul; 21(7):975-84. PubMed ID: 22612537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker.
    Danese S
    Dig Liver Dis; 2008 Jul; 40 Suppl 2():S225-8. PubMed ID: 18598993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokines in inflammatory bowel disease.
    Kmieć Z
    Arch Immunol Ther Exp (Warsz); 1998; 46(3):143-55. PubMed ID: 9704146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in biological therapy for inflammatory bowel disease.
    Kurtovic J; Segal I
    Trop Gastroenterol; 2004; 25(1):9-14. PubMed ID: 15303463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New drug therapies on the horizon for IBD.
    Perrier C; Rutgeerts P
    Dig Dis; 2012; 30 Suppl 1():100-5. PubMed ID: 23075877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging immunological targets in inflammatory bowel disease.
    Monteleone G; Pallone F; MacDonald TT
    Curr Opin Pharmacol; 2011 Dec; 11(6):640-5. PubMed ID: 22000933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New mediators of immunity and inflammation in inflammatory bowel disease.
    Monteleone G; Fina D; Caruso R; Pallone F
    Curr Opin Gastroenterol; 2006 Jul; 22(4):361-4. PubMed ID: 16760750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond tumor necrosis factor: next-generation biologic therapy for inflammatory bowel disease.
    Podolsky DK
    Dig Dis; 2009; 27(3):366-9. PubMed ID: 19786766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The opposing roles of IL-21 and TGFβ1 in chronic inflammatory bowel disease.
    MacDonald TT; Bell I; Monteleone G
    Biochem Soc Trans; 2011 Aug; 39(4):1061-6. PubMed ID: 21787348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolome and inflammasome in inflammatory bowel disease.
    Nanau RM; Neuman MG
    Transl Res; 2012 Jul; 160(1):1-28. PubMed ID: 22687960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.